The 2025 Boao Health Food Science Conference and Expo, a premier event in the health food industry, brought together renowned enterprises and experts from around the world. With the theme of "Promoting Scientific Evidence, Advancing International Cooperation, Leading Technological Innovation," the event featured 2 pre-conferences, 6 major sections, and 16 innovation seminars.

As an industry leader, Seno Biotech responded actively by debuting its innovative low-sodium albumin peptide product, which drew significant attention from attendees. Developed through advanced biotechnology and unique process design, the product significantly reduces sodium content while maintaining the nutritional value and bioactivity of albumin peptides. This innovation meets the growing demand for low-sodium, high-protein nutrition and fills a gap in the market, providing a safer and more effective option for those with specific health needs.

The launch of the low-sodium albumin peptide showcased Seno Biotech’s strong R&D capabilities and commitment to meeting market demands. The company’s research team presented the product’s development journey, technological advantages, and market potential, and engaged in deep exchanges with industry peers to promote the prosperity of the health food sector.

With its debut, Seno’s low-sodium albumin peptide sets a new benchmark for innovation and market development in the industry. The company looks forward to this product leading the new trend in health foods and bringing greater benefits to consumers’ well-being.